25+ Companies are Working to Improve the Acinetobacter Infections Treatment Space | Major Companies- Omnix Medical, AiCuris, Vaxdyn, and Others

DelveInsight's, "Acinetobacter Infections Pipeline Insight, 2023," report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Acinetobacter Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Acinetobacter Infections Pipeline Report

• DelveInsight's Acinetobacter infections pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Acinetobacter infections treatment.

• Key Acinetobacter infections companies such as Entasis Therapeutics, Spero Therapeutics, Omnix Medical, ABAC Therapeutics, Venatorx Pharmaceuticals, TAXIS Pharmaceutical, Vaxdyn, ContraFect Corporation (CFRX), Debiopharm, Idorsia, Telum Therapeutics, Bioharmony Therapeutics, Destiny Pharma, BioVersys, Hoffmann-La Roche, SuperTrans Medical, Agile Biotics, Qpex Biopharma, Antabio, Nosopharm, Aridis Pharmaceuticals, Brii Biosciences, and others.

• Promising Acinetobacter infections pipeline therapies include Sulbactam-durlobactam, SPR206, OMN 7, ESKAPE Pathogens bacteriophages, TP-102, VNRX-5113, VXD-001, Debio1454, TP-6076, BH02, XF-73, BV100, AcinetoVax, RG6006, OMNIvance, PBP inhibitors, NOSO-2G, AR-401, BRII-693, and others.

• The Acinetobacter infections Companies and academics are working to assess challenges and seek opportunities that could influence Acinetobacter infections R&D. The therapies under development are focused on novel approaches for Acinetobacter infections.

Request a sample and discover the recent advances in Acinetobacter Infections Drug Treatment @ Acinetobacter Infections Pipeline Report- https://www.delveinsight.com/sample-request/acinetobacter-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acinetobacter Infections Overview
Acinetobacter are gram-negative aerobic bacilli or coccobacilli that belong to the family Moraxellaceae.They are ubiquitous and can survive on dry surfaces for up to a month and are commonly carried on the skin of health care workers, increasing the likelihood of patients being colonized and medical equipment being contaminated.

Recent Developmental Activities in the Acinetobacter Infections Treatment Landscape

• In December 2022, Brii Biosciences Limited announced progress against its strategic clinical development priorities, including various updates across its pipeline of infectious disease and central nervous system disease candidates. BRII-693 has a highly differentiated safety and efficacy profile to address the most difficult-to-treat Acinetobacter baumannii and Pseudomonas aeruginosa infections resistant to carbapenem. Brii Bio plans to submit a pre-IND to the China NMPA in the first quarter of 2023.

• In November 2022, Innoviva, Inc. announced that the US Food and Drug Administration (FDA) accepted for Priority Review the new drug application (NDA) for SUL-DUR, an investigational drug for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex (ABC), including multi-drug resistant and carbapenem-resistant strains. The Agency is currently planning to hold an advisory committee meeting to discuss this application. The target PDUFA date (or action date) is May 29, 2023.

• In June 2022, BioVersys AG, announced that it had raised CHF 24.2 million in the first closing of its Series C round. This first closing was significantly oversubscribed by both existing and new investors from diverse geographies. BioVersys intends to complete the Series C investment round by the end of 2022. The company will use the investment to initiate first Phase II clinical trials of BV100 and BVL-GSK098 and the preclinical development of BV200. BV100 addresses serious infections caused by Carbapenem-Resistant Acinetobacter baumannii (CRAB) in hospitalized patients, where mortality currently reaches 50% while BVL-GSK098 targets the 10 million tuberculosis (TB) sufferers identified each year, of which 1.5 million die every year.

• Debiopharm is developing Debio 1454, a FabI inhibitor targeting a combination of enteric bacteria species, A. baumannii, Enterobacter Spp., Klebsiella pneumoniae and E.coli. This compound belongs to a family of narrow-spectrum antiobiotics that combines a very potent activity on pathogens of interest while reducing the selective pressure on other bacterial strains and sparing the microbiome.

Find out more information of the latest Drugs Launch, News, and Breakthroughs of the Acinetobacter Infections Pipeline Report @ Latest Acinetobacter Infections Drugs Launch- https://www.delveinsight.com/sample-request/acinetobacter-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acinetobacter Infections Emerging Drugs Profile

• Sulbactam-durlobactam: Entasis Therapeutics
Durlobactam (DUR; previously designated ETX2514) is a novel, broad-spectrum and potent inhibitor of Class A, C, and D β-lactamases. Sulbactam (SUL) is a β-lactam antibiotic with activity against Acinetobacter baumannii; however, β-lactamase-mediated resistance to sulbactam is now widespread rendering it generally ineffective. In preclinical studies, durlobactam inhibits the β-lactamases commonly found in A. baumannii thus restoring sulbactam's activity. The company is developing SUL-DUR (previously designated ETX2514SUL), a combination of β-lactam antibiotic and a β-lactamase inhibitor for the treatment of serious infections cuased by Acinetobacter, including multidrug-resistant (MDR) strains. In October 2021 the company announced positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant ABC infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. SUL-DUR has been designated a Qualified Infectious Disease Product (QIDP) by the U.S. Food and Drug Administration and awarded Fast Track status.

Acinetobacter Infections Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Acinetobacter Infections. The companies which have their Acinetobacter Infections drug candidates in the most advanced stage, i.e. phase III include, Entasis Therapeutics.

Learn more about the emerging Acinetobacter Infections pipeline therapies @ Acinetobacter Infections Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/acinetobacter-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Acinetobacter Infections Pipeline Report

• Coverage- Global

• Acinetobacter infections Companies- Entasis Therapeutics, Spero Therapeutics, Omnix Medical, ABAC Therapeutics, Venatorx Pharmaceuticals, TAXIS Pharmaceutical, Vaxdyn, ContraFect Corporation (CFRX), Debiopharm, Idorsia, Telum Therapeutics, Bioharmony Therapeutics, Destiny Pharma, BioVersys, Hoffmann-La Roche, SuperTrans Medical, Agile Biotics, Qpex Biopharma, Antabio, Nosopharm, Aridis Pharmaceuticals, Brii Biosciences, and others.

• Acinetobacter infections Pipeline Therapies- Sulbactam-durlobactam, SPR206, OMN 7, ESKAPE Pathogens bacteriophages, TP-102, VNRX-5113, VXD-001, Debio1454, TP-6076, BH02, XF-73, BV100, AcinetoVax, RG6006, OMNIvance, PBP inhibitors, NOSO-2G, AR-401, BRII-693, and others.

• Acinetobacter infections Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Acinetobacter Infections Market Drivers and Acinetobacter Infections Market Barriers, click here @ Acinetobacter Infections Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/acinetobacter-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Acinetobacter Infections: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Acinetobacter Infections - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Acinetobacter Infections Collaboration Deals
9. Late Stage Products (Phase III)
10. Sulbactam-durlobactam: Entasis Therapeutics
11. Drug profiles in the detailed report…..
12. Preclinical and Discovery Stage Products
13. SPR 206: Spero Therapeutics
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Acinetobacter Infections Key Companies
17. Acinetobacter Infections Key Products
18. Acinetobacter Infections- Unmet Needs
19. Acinetobacter Infections- Market Drivers and Barriers
20. Acinetobacter Infections- Future Perspectives and Conclusion
21. Acinetobacter Infections Analyst Views
22. Acinetobacter Infections Key Companies
23. Appendix

Got Queries? Find out the related information on Acinetobacter Infections Mergers and acquisitions, Acinetobacter Infections Licensing Activities @ Acinetobacter Infections Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/acinetobacter-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.